SUMMARY
Over the last decades, significant progress is made in the treatment of patients with solid cancers. Especially advancements in chemotherapy, hormonal therapy, targeted therapy and immunotherapy has led to the improvement of treatment outcome and an increase in the disease-free and overall survival of cancer patients. To further improve the treatment outcome for patients with solid cancers, a dedicated technique is necessary to improve diagnoses, monitor treatment response and select patients for the most optimal treatment strategy in real-time. Furthermore, the development of intraoperative techniques that improves the surgical treatment of locoregional disease is stagnating. Surgeons are still mainly dependent on visual inspection and palpation to discriminate malignant tissue from benign tissue, most likely leading to undertreatment and overtreatment of patients. Molecular fluorescence imaging allows real-time imaging of tumor tissue by enabling visualization of tumor-specific, upregulated proteins and biological processes involved in oncogenesis using targeted fluorescent tracers, and therefore might be the ideal imaging modality to be used during surgery and endoscopy. [1] [2] [3] This thesis describes the potential of molecular fluorescence imaging to facilitate clinicians in real-time clinical decision making and individualized treatment of patients with solid cancers and can serve as an innovative tool for drug development purposes.
Chapter 1 provides a general introduction and outline of the thesis. In Chapter 2, a novel analytical framework for the clinical translation and evaluation of tumor-targeted tracers for molecular fluorescence imaging is described. By combining multiple complementary state-of-the-art clinical optical imaging techniques, the tumor-specific targeting of breast cancer with bevacizumab-800CW in escalating doses is confirmed by tracing down bevacizumab-800CW on both a macroscopic and microscopic level. Within the individual components of the novel analytical framework, we showed that the intraoperative detection of tumor-involved margins is much better than standard surgical practice. An 88% increase in intraoperative detection of tumor-positive resection margins is observed, that was otherwise missed by intraoperative assessment of surgical margins using standard visual inspection and palpation. Therefore, intraoperative realtime detection of the tumor-involved surgical margins might lead to prevention of undertreatment in the future, because in these patients, additional surgery or therapy might have avoided. In this chapter, the clinical value of intraoperative molecular fluorescence imaging in breast cancer patients is shown, which supports a paradigm shift in the future surgical treatment of breast cancer patients.
Besides a tool for intraoperative decision making in breast cancer, molecular fluorescence imaging might be beneficial in patients with peritoneal carcinomatosis 7 151 of colorectal origin for the improved detection of lesions intraoperatively. The intraoperative assessment of the tumor load during the cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedure is important to carefully select patients that might benefit from the extensive treatment; and secondly to achieve a complete cytoreduction, which is associated with increased overall survival. In the feasibility study in Chapter 3, we show on a macroscopic and microscopic level, that bevacizumab-800CW accumulates in peritoneal metastases of colorectal origin. In cancer surgery, it is crucial to leave no residual disease. However, resection of multiple different organs is associated with substantial morbidity. 4 Interestingly, all intraoperative non-fluorescent lesions detected by the surgeons proved to be benign. Consequently, the added value of molecular fluorescence imaging during CRS-HIPEC procedure in treatment of patients with peritoneal metastases of colorectal origin is the potential prevention of overtreatment, meaning if a surgeon identifies a suspicious peritoneal lesion by visual inspection and palpation that is non-fluorescent, it could safely be left in situ. The results in this chapter are the basis to provide supportive data for changing the standard of care in patients with peritoneal carcinomatosis of colorectal cancer origin undergoing cytoreduction and HIPEC using molecular fluorescence-guided surgery.
Besides guiding intraoperative decision making, the impact of fluorescence imaging on the workflow of pathological analysis can be significant. Due to practical and logistical constraints, the surgical specimen cannot be completely (i.e. every millimeter) evaluated by histology. Therefore, the fresh surgical specimen is grossly examined by visual inspection and palpation by the attending pathologist for the sampling of tissue, potentially causing sampling error. To optimize current tissue sampling procedures and prevent sampling errors, as result of macroscopic fluorescence imaging of the fresh surgical specimen and the fresh tissue slices the pathologist is provided with a redflag technique that precisely outlines tumor tissue (i.e., fluorescence-guided pathology (FGP)). Additionally, fluorescence guided pathology might be applied in the surgical theater during surgery, leading to a direct impact on intraoperative clinical decision making of the surgeon. Currently, the surgeon is depended on the final histological analyses which is known in five working days after the surgery. By applying fluorescence guided pathology, the surgeon can act directly in case of a tumor positive margin by an additional resection. This could improve surgical and clinical outcome. Tumor-positive surgical margins are detected in 18% of patients with locally advanced rectal cancer that are curatively treated with neoadjuvant chemoradiotherapy followed by surgery. In Chapter 4, by using FGP we correctly predicted a tumor negative circumferential resection margin (CRM) status in 5/6 patients (83%) with colorectal cancer with a tumornegative CRM. In 1 of 2 patients (50%) with a tumor-positive CRM, FGP correctly predicted a positive CRM status by high fluorescence intensities. The patient with a low fluorescent tumor had microscopic tumor cells within 1 mm of the CRM. Furthermore, bevacizumab-800CW discriminates colorectal cancer form normal colorectal tissue with a sensitivity and specificity of 98.2% and 76.8% respectively.
Integration of diagnostics and therapeutics by fluorescent labeling of drugs, i.e. theranostics, can provide insight in pharmacokinetics, tumor uptake, and biodistribution of drugs and might be used for treatment monitoring. Two clinical advantages can be distinguished: first, by enabling visualization of molecular characteristics of the tumor to stratify patients for the most optimal targeted therapy and second, by aiding in monitoring treatment response, assisting clinicians to adjust therapy dose or to switch to another targeted drug. To implement theranostics in clinical oncology, a dedicated technique is necessary to diagnose, monitor treatment response and select patients for the most optimal treatment strategy. By molecular fluorescence endoscopy, the presence of targeted fluorescent tracers in tissue can be visualized and quantified real-time, which can be correlated to the biological target expression to monitor treatment response. Chapter 5 describes the first clinical trial that investigates the impact of quantitative fluorescence endoscopy (QFE) for tumor response evaluation after neoadjuvant chemoradiotherapy using bevacizumab-800CW in patients with locally advanced rectal cancer. Multi Diameter Single Fiber Reflectance and Single Fiber Fluorescence (MDSFR/ SFF) spectroscopy is used to enable real-time quantification of the fluorescence signals. MDSFR/SFF spectroscopy is a technique that corrects the measured fluorescence signals for tissue optical properties like scattering and absorption. 5 The correction of fluorescence signals for tissue optical properties is of additional value because the optical properties influence the measured fluorescence intensity, potentially leading to over or underestimation of the accumulation of the tracer and thus the actual biology, and potentially leading to incorrect recommendations in clinical practice that might lead to inferior outcomes for the patients. Tumor tissue showed significant higher fluorescence compared to normal rectal tissue and fibrosis, with an area under curve of 0.925. Especially in patients without endoluminal tumor, but with tumor nests in the submucosal layers, QFE might have a great impact in restaging diagnosis and correctly stratify these patients to the optimal treatment regimen, i.e. watchful waiting or surgical treatment. In patients with submucosal tumor nests normal white light endoscopy can be false negative, whereas QFE using a tracer that accumulates in the microenvironment of a tumor, like bevacizumab-800CW, targets the microenvironment that has not been normalized in these patients. In the study described in Chapter 5, QFE would have changed the restaging diagnosis correctly in 4 / 25 patients (16%), signifying QFE as promising tool to aid response assessment after neoadjuvant chemoradiotherapy in LARC patients. QFE could markedly enhance the accuracy of treatment response evaluation even in the presence of tissue fibrosis and ulcers after neoadjuvant therapy, 7 153 and thus improve the selection of patients for organ-preserving strategies.
To optimally implement the theranostic approach in oncology, relevant targets need to be identified and prioritized. In Chapter 6, we used functional genomic messenger RNA (FGmRNA) profiling to predict target upregulation on the protein level in pancreatic cancer, to facilitate clinicians and drug developers in deciding which theranostic targets should be taken into further evaluation in pancreatic cancer to improve the poor outcome of pancreatic cancer patients. The ideal theranostic target has a limited expression at the cell membrane of normal cells and is highly overexpressed at the cell membrane of tumor cells. We identified 213 significantly upregulated proteins in PDA compared with normal pancreatic tissue. Mucin-1, mesothelin, g-glutamyltransferase 5, and cathepsin-E as are prioritized as the most interesting targets, because great potential was already shown in literature in the clinical translation process and are therefore high potential targets for clinical translation in pancreatic cancer patients on the short term.
Beside guiding clinicians in selecting theranostic targets, FGmRNA profiling can help researchers and clinicians in selecting targets for molecular imaging probes. Molecular imaging might enable visualization of small PDA lesions, enhancing disease staging and causing optimized selection of patients who will benefit from curative surgery. Only 7 of the 41 currently druggable targets are currently described in literature in the context of molecular imaging, indicating the great potential for the development of favorable molecular imaging probes.
FUTURE PERSPECTIVES
Although the early clinical studies described in this thesis are demonstrating the great potential of the clinical application of molecular fluorescence imaging, certain steps need to be taken before this technique will lead to a paradigm shift in clinical cancer treatment.
First, the fluorescence camera system of our setup is still in development and improvements with regard to interpretation of fluorescence signals and intraoperative quantification have not been finalized yet. Improvements such as multispectral subtraction techniques might be useful in separating the fluorescence spectrum of our near-infrared dye from other (auto-)fluorescence signals, such as foreign body inclusions. Furthermore, by improving intraoperative quantification of fluorescence signals, e.g. by MDFSR/SFF spectroscopy, a threshold could be set to distinguish fluorescence intensities derived from benign and tumor lesions, facilitating real-time clinical decision making. Moreover, some body cavities are very difficult for homogenous illumination and excitation of the fluorescent tracers, e.g. the pelvic region. This may be overcome by using a more flexible fluorescence laparoscope or robotic fluorescence imaging system. However, currently available fluorescence laparoscopy and robotic systems lack significant sensitivity to detect the current tracer concentrations, so this technique needs further refinement. Furthermore, the intrinsic limitations of light propagation in tissue limits depth penetration decreasing the visualization of tumor in deeper layers of the tissue. Future complementary detection systems such as optoacoustic imaging may further improve the detection of tumor specific fluorescent tracers for clinical decision making. Optoacoustic imaging combines the rich contrast of optical imaging with the higher penetration of radiofrequency waves, enhancing visualization of tumor in deeper layers of the tissue. Furthermore, by using multiple wavelengths optoacoustic imaging can provide more detailed information about tumor heterogeneity when a cocktail of tracers with different excitation and emission wavelengths is used, that might lead to even more improved clinical decisions.
Besides optimization of the fluorescence detection system, the sensitivity and specificity of the fluorescent tracers that we used can be improved, by using not only antibody-based tracers, but using small peptides or even small activatable probes that are only fluorescent in certain circumstances, e.g. certain pH levels or certain protein concentrations. Additionally, we need to learn more about the optimal tracer dose for each cancer type and for each application. In the clinical trials of the current thesis, most often a micro dose is used. In the clinical study in breast cancer patients (Chapter 2) escalating doses were given. In this trial, we observed a large variation in fluorescence intensities between patients of higher dose groups. Clinicopathological parameters like tumor size, tumor grade, tumor type and hormonal status are influencing protein expression and therefore the correlation of tracer uptake with clinicopathological parameters. To draw definitive conclusions about the optimal tracer dose, more research in larger patient groups is needed.
The clinical trials described in this thesis are set up as feasibility trials, and we followed the current clinical workflow to not interfere the clinical standards. To further increase the real-time intraoperative clinical decision making by the surgeon, fluorescence guided pathology might be already applied in the surgical theater. Fluorescence guided pathology might bridge the time-gap between the current intraoperative decision making of the surgeon and the determination of presence or absence of a tumor positive margin by the pathologist. This requires a more dynamic interaction between in vivo intraoperative imaging and ex vivo macroscopic imaging of the surgical specimen. When fluorescence images of the intraoperative field and the surgical specimen can be provided to both disciplines simultaneously, there is a direct impact on clinical decision making with the optimal benefit for the individual patient. Moreover, in case of residual tumor, theranostic applications such as targeted photodynamic therapy can be applied simultaneously or subsequently after resection during surgery.
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In this thesis molecular imaging was studied in only a few solid cancer types. The main advantage of the technique is the broad application in surgery and gastroenterology, besides, molecular fluorescence imaging can be beneficial for all tumor types that can be reached by an endoscope, e.g. lung cancers and bronchial cancers, and oro-laryngeal cancers. Also, all diseases that are treated with antibody therapies, such as inflammatory bowel disease and rheumatoid arthritis, might be diagnosed and monitored using fluorescence molecular imaging, and as is the case within the treatment of infectious diseases, for example in orthopedics to diagnose peri-prothesis infections. Furthermore, an interesting application for molecular imaging is the additional value in the field of drugdevelopment. Molecular imaging demonstrates the on-and off target characteristics of a fluorescently labelled drug on a macroscopic and microscopic levels, and can aid in precision drug development by enhancing the decision-making progress for a go/no-go to support and the selection of the most potent drugs for the target population in an early stage. Therefore, molecular fluorescence imaging in drug development is potentially reducing significant costs by obtaining an earlier 'quick win -fast fail' scenario. 6 
MAIN CONCLUSION
This thesis describes the potential of molecular fluorescence imaging for clinical decision making during surgery as well as during endoscopy. This technique has the potential to improve diagnosing, monitoring treatment response and selection of patients for the most optimal treatment strategy, potentially leading to improve the outcome of patients with solid cancers. The results in this thesis provides the data that support further clinical translation of molecular fluorescence imaging that will lead to a paradigm shift in the treatment of solid cancers.
